{"id":"poor-metabolisers","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Poor metabolisers refers to a patient phenotype, not a therapeutic agent. It describes individuals who carry genetic variants (typically loss-of-function mutations) in cytochrome P450 enzymes or other metabolic pathways, resulting in significantly reduced drug clearance. This classification is used to guide personalized dosing and drug selection to prevent adverse events from drug accumulation.","oneSentence":"Poor metabolisers is not a drug but a pharmacogenetic classification describing individuals with reduced capacity to metabolize certain medications due to genetic variations in drug-metabolizing enzymes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:52.818Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02248259","phase":"PHASE1","title":"Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-08","conditions":"Healthy","enrollment":25},{"nctId":"NCT04619927","phase":"PHASE4","title":"Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-03-01","conditions":"Peripheral Arterial Disease","enrollment":2276},{"nctId":"NCT03103646","phase":"PHASE1","title":"Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2017-03-28","conditions":"Cytochrome P450 Interaction","enrollment":22},{"nctId":"NCT00803673","phase":"PHASE1","title":"A Healthy Volunteer Study With Inhaled GSK573719 and Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":36},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT00713765","phase":"PHASE1","title":"Pharmacokinetic Interaction Between AZD3480 and Donepezil","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":33},{"nctId":"NCT02191176","phase":"PHASE1","title":"Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT01478490","phase":"PHASE1","title":"To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-09","conditions":"Pharmacokinetics of Mirabegron, Healthy Subjects","enrollment":28},{"nctId":"NCT00686179","phase":"PHASE1","title":"Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Healthy","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":257,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Poor metabolisers","genericName":"Poor metabolisers","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}